Literature DB >> 22065001

Inter-ethnic differences--how important is it in cancer treatment?

Winnie H Y Ling1, Soo Chin Lee.   

Abstract

It is now well recognised that there are inter-ethnic differences accounting for variations in both pharmacokinetics (PK) and pharmacodynamics (PD) of drugs, resulting in differences in drug responses. Treating physicians should be aware of pharmacogenetic differences that may exist between the races while extrapolating data generated from other populations to their own patients in order to ensure optimal treatment response and minimise toxicity. This is especially crucial in the practice of oncology where many anti-cancer drugs have narrow therapeutic indices. This paper discusses some commonly used drugs in cancer treatment where inter-ethnic differences in drug safety and efficacy are known to exist that are relevant to the Asian physician.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065001

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  16 in total

1.  Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.

Authors:  Nelson L S Tang; Chen Di Liao; Xingyan Wang; Frankie K F Mo; Vicky T C Chan; Rita Ng; Elizabeth Pang; Joyce J S Suen; Jean Woo; Winnie Yeo
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-10       Impact factor: 4.553

2.  Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.

Authors:  Colby S Shemesh; Phyllis Chan; Hui Shao; Derek-Zhen Xu; Daniel Combs; Shweta Vadhavkar; René Bruno; Benjamin Wu
Journal:  Liver Cancer       Date:  2021-06-10       Impact factor: 11.740

3.  Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trials.

Authors:  Xiaoning Guo; Xiaohui Wang; Sui Shen; Bryan Oronsky; Tony R Reid; Meaghan Stirn; Scott Caroen; Franck Brinkhaus; Nacer A Abrouk; Liandai Yang; Lianzong Wu; Zhongwen Yu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

4.  Ethnic disparities in trauma mortality outcomes.

Authors:  Jeffrey J Leow; Vanessa W Lim; Pravin Lingam; Karen T S Go; Li Tserng Teo
Journal:  World J Surg       Date:  2014-07       Impact factor: 3.352

5.  Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study.

Authors:  Jasmina Obradović; Natasa Djordjević; Natasa Tošic; Jasminka Mrdjanović; Biljana Stanković; Jelena Stanić; Bojan Zarić; Branislav Perin; Sonja Pavlović; Vladimir Jurišić
Journal:  Tumour Biol       Date:  2016-02-05

6.  PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients.

Authors:  Hiroji Iwata; Seock-Ah Im; Norikazu Masuda; Young-Hyuck Im; Kenichi Inoue; Yoshiaki Rai; Rikiya Nakamura; Jee Hyun Kim; Justin T Hoffman; Ke Zhang; Carla Giorgetti; Shrividya Iyer; Patrick T Schnell; Cynthia Huang Bartlett; Jungsil Ro
Journal:  J Glob Oncol       Date:  2017-04-11

7.  Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations.

Authors:  Angela Roco; Luis Quiñones; José A G Agúndez; Elena García-Martín; Valentina Squicciarini; Carla Miranda; Joselyn Garay; Nancy Farfán; Iván Saavedra; Dante Cáceres; Carol Ibarra; Nelson Varela
Journal:  Front Genet       Date:  2012-11-02       Impact factor: 4.599

8.  Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

Authors:  Shinzaburo Noguchi; Norikazu Masuda; Hiroji Iwata; Hirofumi Mukai; Jun Horiguchi; Puttisak Puttawibul; Vichien Srimuninnimit; Yutaka Tokuda; Katsumasa Kuroi; Hirotaka Iwase; Hideo Inaji; Shozo Ohsumi; Woo-Chul Noh; Takahiro Nakayama; Shinji Ohno; Yoshiaki Rai; Byeong-Woo Park; Ashok Panneerselvam; Mona El-Hashimy; Tetiana Taran; Tarek Sahmoud; Yoshinori Ito
Journal:  Breast Cancer       Date:  2013-02-13       Impact factor: 4.239

9.  Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.

Authors:  Tomoko Hasunuma; Masahiro Tohkin; Nahoko Kaniwa; In-Jin Jang; Cui Yimin; Masaru Kaneko; Yoshiro Saito; Masahiro Takeuchi; Hiroshi Watanabe; Yasushi Yamazoe; Yoshiaki Uyama; Shinichi Kawai
Journal:  Br J Clin Pharmacol       Date:  2016-03-14       Impact factor: 4.335

10.  Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics.

Authors:  Sze Ling Chan; Nilakshi Samaranayake; Colin J D Ross; Meng Tiak Toh; Bruce Carleton; Michael R Hayden; Yik Ying Teo; Vajira H W Dissanayake; Liam R Brunham
Journal:  Pharmacogenet Genomics       Date:  2016-01       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.